US5453566A
(en)
|
1986-03-28 |
1995-09-26 |
Calgene, Inc. |
Antisense regulation of gene expression in plant/cells
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
US4987071A
(en)
|
1986-12-03 |
1991-01-22 |
University Patents, Inc. |
RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
|
JP3046318B2
(ja)
|
1987-12-15 |
2000-05-29 |
ジーン・シアーズ・ピーティーワイ・リミテッド |
リボザイム
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
GB8822492D0
(en)
|
1988-09-24 |
1988-10-26 |
Considine J |
Apparatus for removing tumours from hollow organs of body
|
US5211657A
(en)
|
1988-11-07 |
1993-05-18 |
The United States Government As Represented By The Secretary Of The Department Of Health And Human Services |
Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
US5549910A
(en)
|
1989-03-31 |
1996-08-27 |
The Regents Of The University Of California |
Preparation of liposome and lipid complex compositions
|
EP0438803B1
(en)
|
1990-01-26 |
1997-03-12 |
Immunomedics, Inc. |
Vaccines against cancer and infectious diseases
|
JP3218637B2
(ja)
|
1990-07-26 |
2001-10-15 |
大正製薬株式会社 |
安定なリポソーム水懸濁液
|
US5789573A
(en)
|
1990-08-14 |
1998-08-04 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
|
JP2958076B2
(ja)
|
1990-08-27 |
1999-10-06 |
株式会社ビタミン研究所 |
遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
|
IL108367A0
(en)
|
1993-01-27 |
1994-04-12 |
Hektoen Inst For Medical Resea |
Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
|
SE9301916D0
(sv)
|
1993-06-03 |
1993-06-03 |
Ab Astra |
New peptides derivatives
|
SE9301911D0
(sv)
|
1993-06-03 |
1993-06-03 |
Ab Astra |
New peptide derivatives
|
US5801154A
(en)
|
1993-10-18 |
1998-09-01 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of multidrug resistance-associated protein
|
ZA951617B
(en)
|
1994-03-04 |
1997-02-27 |
Lilly Co Eli |
Antithrombotic agents.
|
US5741516A
(en)
|
1994-06-20 |
1998-04-21 |
Inex Pharmaceuticals Corporation |
Sphingosomes for enhanced drug delivery
|
US5795587A
(en)
|
1995-01-23 |
1998-08-18 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
US5738868A
(en)
|
1995-07-18 |
1998-04-14 |
Lipogenics Ltd. |
Liposome compositions and kits therefor
|
US5739119A
(en)
|
1996-11-15 |
1998-04-14 |
Galli; Rachel L. |
Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA
|
US5866573A
(en)
|
1997-04-21 |
1999-02-02 |
Merck & Co., Inc. |
Pyrazinone thrombin inhibitors
|
EP1082324A4
(en)
|
1998-05-26 |
2002-01-02 |
Merck & Co Inc |
IMIDAZOPYRIDINE COMPOUNDS AS THROMBINE INHIBITORS
|
KR20000047461A
(ko)
|
1998-12-29 |
2000-07-25 |
성재갑 |
트롬빈 억제제
|
AU3192500A
(en)
|
1999-03-16 |
2000-10-04 |
C & C Research Laboratories |
Substituted proline derivatives and medicinal compositions containing the same
|
BR0011295A
(pt)
|
1999-05-19 |
2002-05-28 |
Pharmacia Corp |
Aril e heteroaril pirazinonas policìclicas substituìdas úteis para inibição seletiva de cascata de coagulação
|
US6653316B1
(en)
|
1999-05-19 |
2003-11-25 |
Pharmacia Corporation |
Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
|
US7015230B1
(en)
|
1999-05-19 |
2006-03-21 |
Pharmacia Corporation |
Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
|
US6664255B1
(en)
|
1999-05-19 |
2003-12-16 |
Pharmacia Corporation |
Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
|
US20040072862A1
(en)
|
1999-06-04 |
2004-04-15 |
Bitler Catherine M. |
Compositions for treating ischemia-related neuronal damage
|
US6649592B1
(en)
|
2000-01-14 |
2003-11-18 |
Science & Technology Corporation @ Unm |
Peptide inhibitors of LFA-1/ICAM-1 interaction
|
SG98393A1
(en)
|
2000-05-19 |
2003-09-19 |
Inst Materials Research & Eng |
Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
|
JP2004516286A
(ja)
|
2000-12-18 |
2004-06-03 |
メルク エンド カムパニー インコーポレーテッド |
ベンジルアミン誘導体およびそれのトロンビン阻害薬としての使用
|
JP2005514332A
(ja)
|
2001-10-03 |
2005-05-19 |
ファルマシア・コーポレーション |
凝固カスケードの選択阻害に有用な6員不飽和複素環式化合物
|
JP2005509606A
(ja)
|
2001-10-03 |
2005-04-14 |
ファルマシア・コーポレーション |
凝血カスケードを選択的に阻害するのに有用な置換された多環式化合物のプロドラッグ
|
JP4723244B2
(ja)
|
2002-07-19 |
2011-07-13 |
オメロス コーポレイション |
生分解性トリブロックコポリマー、その合成方法、ならびにそれから作製されるヒドロゲルおよび生体材料
|
AU2003299901A1
(en)
|
2002-10-04 |
2004-05-04 |
Merck And Co., Inc. |
Thrombin inhibitors
|
US7482376B2
(en)
|
2003-07-03 |
2009-01-27 |
3-Dimensional Pharmaceuticals, Inc. |
Conjugated complement cascade inhibitors
|
CA2847677C
(en)
|
2004-06-10 |
2018-05-01 |
Omeros Corporation |
Methods for treating conditions associated with masp-2 dependent complement activation
|
US8840893B2
(en)
|
2004-06-10 |
2014-09-23 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
US20140056873A1
(en)
|
2004-06-10 |
2014-02-27 |
University Of Leicester |
Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
|
US7919094B2
(en)
|
2004-06-10 |
2011-04-05 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
AU2006227778A1
(en)
*
|
2005-03-16 |
2006-09-28 |
Janssen Pharmaceutica N.V. |
Novel thiophene sulfoximines for treating complement-mediated diseases and conditions
|
WO2008085608A1
(en)
|
2007-01-10 |
2008-07-17 |
Irm Llc |
Compounds and compositions as channel activating protease inhibitors
|
DE102009004113A1
(de)
|
2009-01-08 |
2010-07-15 |
Giesecke & Devrient Gmbh |
Verfahren zur Installation einer elektronischen Ticket- und/oder Bezahl-Applikation auf einem mobilen Endgerät
|
TW201100441A
(en)
|
2009-06-01 |
2011-01-01 |
Osi Pharm Inc |
Amino pyrimidine anticancer compounds
|
RU2600876C2
(ru)
|
2009-10-16 |
2016-10-27 |
Омерос Корпорейшен |
Способ лечения диссеминированного внутрисосудистого свертывания крови путем ингибирования masp-2 зависимой активации комплемента
|
HUP1000366A2
(en)
|
2010-07-13 |
2012-03-28 |
Mta Enzimologiai Intezet |
Novel proteins, their production process and use tereof
|
US9644035B2
(en)
|
2011-04-08 |
2017-05-09 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
NZ746139A
(en)
|
2011-04-08 |
2023-11-24 |
Omeros Corp |
Methods for treating conditions associated with masp-2 dependent complement activation
|
RS60541B1
(sr)
|
2011-05-04 |
2020-08-31 |
Omeros Corp |
Kompozicije za inhibiciju masp-2 zavisne aktivacije komplementa
|
AU2013201779B2
(en)
|
2011-05-04 |
2016-01-07 |
Omeros Corporation |
Compositions for inhibiting MASP-2 dependent complement activation
|
RU2666530C2
(ru)
|
2012-01-12 |
2018-09-11 |
Йейл Юниверсити |
Соединения и способы усиления деградации белков-мишеней и других полипептидов с помощью е3 убиквитин лигазы
|
HUE036930T2
(hu)
|
2012-04-06 |
2018-08-28 |
Omeros Corp |
Készítmények és eljárások MASP-1 és/vagy MASP-3 gátlására paroxymalis nocturnalis hemoglobinürítés kezelésére
|
RS61755B1
(sr)
|
2012-06-18 |
2021-05-31 |
Omeros Corp |
Kompozicije i postupci za inhibiciju masp-1 i/ili masp-2 i/ili masp-3 za tretman različitih bolesti i poremećaja
|
TW201402613A
(zh)
*
|
2012-06-19 |
2014-01-16 |
必治妥美雅史谷比公司 |
Iap拮抗劑
|
EP2922535B1
(en)
*
|
2012-11-20 |
2021-11-10 |
Merck Sharp & Dohme Corp. |
Thrombin inhibitors
|
KR20160062186A
(ko)
|
2013-10-17 |
2016-06-01 |
오메로스 코포레이션 |
Masp-2 의존성 보체 활성화와 관련된 상태의 치료 방법
|
EA032713B1
(ru)
|
2013-12-30 |
2019-07-31 |
Лайфсай Фармасьютикалс, Инк. |
Терапевтические ингибирующие соединения
|
IL259225B
(en)
|
2015-11-09 |
2022-09-01 |
Omeros Corp |
Preparations containing antibodies that suppress masp-2 and antigen-binding fragments for use in the treatment of tma associated with hematopoietic stem cell transplantation
|
US20170253667A1
(en)
|
2016-01-05 |
2017-09-07 |
University Of Leicester |
Methods for inhibiting fibrosis in a subject in need thereof
|
AU2017205453B2
(en)
|
2016-01-05 |
2020-03-12 |
Omeros Corporation |
Methods for inhibiting fibrosis in a subject in need thereof
|
MX2018011648A
(es)
|
2016-03-31 |
2019-01-30 |
Omeros Corp |
Metodos para la inhibicion de fibrosis en un sujeto en necesidad del mismo.
|
JOP20170170B1
(ar)
|
2016-08-31 |
2022-09-15 |
Omeros Corp |
صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
|
US20180105604A1
(en)
|
2016-10-13 |
2018-04-19 |
University Of Leicester |
Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy
|
TWI818919B
(zh)
|
2017-08-15 |
2023-10-21 |
美商歐米諾斯公司 |
用於治療和/ 或預防與造血幹細胞移植有關的移植物抗宿主病和/ 或瀰漫性肺泡出血和/ 或靜脈閉塞性病的方法
|
IL272573B2
(en)
|
2017-09-13 |
2023-10-01 |
Amgen Inc |
Sarcomere activating bisamide compounds and their uses
|
GB201805174D0
(en)
*
|
2018-03-29 |
2018-05-16 |
Univ Leeds Innovations Ltd |
Compounds
|
GB201807014D0
(en)
*
|
2018-04-30 |
2018-06-13 |
Univ Leeds Innovations Ltd |
Factor xlla inhibitors
|
SG11202010925UA
(en)
*
|
2018-05-29 |
2020-12-30 |
Omeros Corp |
Masp-2 inhibitors and methods of use
|
CN115052862A
(zh)
|
2019-12-04 |
2022-09-13 |
奥默罗斯公司 |
Masp-2抑制剂和使用方法
|
WO2021113698A1
(en)
|
2019-12-04 |
2021-06-10 |
Omeros Corporation |
Masp-2 inhibitors and methods of use
|
US20210179612A1
(en)
|
2019-12-04 |
2021-06-17 |
Omeros Corporation |
Masp-2 inhibitors and methods of use
|